Clindamycin Phosphate 1.2%/Adapalene 0.15%/Benzoyl Peroxide 3.1% Gel for Male and Female Acne: Phase 3 Analysis

October 2024 | Volume 23 | Issue 10 | Original Article | 873 | Copyright © October 2024

Preference for Cal/BDP Cream or Foam in Patients With Mild to Moderate Plaque Psoriasis

August 2024 | Volume 23 | Issue 8 | Original Article | 607 | Copyright © August 2024

INDIVIDUAL ARTICLE: Vehicles Matter!

February 2024 | Volume 23 | Issue 2 | Supplement Individual Articles | SF378969s3 | Copyright © February 2024

Read More

Patient Preference for Calcipotriene and Betamethasone Dipropionate Cream Versus Foam for the Topical Treatment of Psoriasis: A Pilot Study

March 2023 | Volume 22 | Issue 3 | Original Article | 271 | Copyright © March 2023

Supplement Individual Article: Oldie But Goodie

January 2023 | Volume 22 | Issue 1 | Supplement Individual Articles | 3446172 | Copyright © January 2023

Research over the past several years has elucidated the pathophysiology of psoriasis, yielding both new treatment options and enhanced knowledge of the mechanisms of action of existing treatments....
Read More

Supplement Individual Article: A Reappraisal of Fixed-Combination Halobetasol Propionate and Tazarotene for the Treatment of Psoriasis: Biological Underpinnings, Therapeutic Mechanisms, and Economic Considerations

January 2023 | Volume 22 | Issue 1 | Supplement Individual Articles | 3446174 | Copyright © January 2023

Psoriasis is a complex inflammatory disease, which can be triggered by the interplay among keratinocytes, various immune cells, and even dermal vascular endothelial cells. Understanding of the key pla...
Read More

SUPPLEMENT INDIVIDUAL ARTICLES: Update on Truncal Acne: A Review of Treatments for a Neglected Disease and the Re-Emergence of Tazarotene

December 2022 | Volume 21 | Issue 12 | Supplement Individual Articles | SF3446185 | Copyright © December 2022

Acne vulgaris of the trunk carries with it a major psychosocial impact and an unmet need for adequate management. Approximately 50% of patients with facial acne also exhibit involvement of the back, c...
Read More

SUPPLEMENT INDIVIDUAL ARTICLES: "Vehicles Matter" in the Treatment of Truncal Acne

December 2022 | Volume 21 | Issue 12 | Supplement Individual Articles | SF3446183 | Copyright © December 2022

Among the general population and arguably among most dermatologists, the word acne calls to mind images of a teenager with papules and pustules on the face. Yet, we know that acne is not just a diseas...
Read More

The Maintenance Effect of Calcipotriene 0.05% and Betamethasone Dipropionate 0.064% (Cal/BD) Aerosol Foam in Combination With Apremilast

April 2022 | Volume 21 | Issue 4 | Original Article | 381 | Copyright © April 2022

Even in light of significant recent therapeutic advancements, many patients with psoriasis will use a combination of treatments at some point in the disease course. Despite the frequency with which co...
Read More

In Vitro Rheology Predicts Improved Spreadability of Tazarotene 0.045% Lotion Versus Trifarotene 0.005% Cream

March 2022 | Volume 21 | Issue 3 | Original Article | 250 | Copyright © March 2022

Background: Intrinsic properties of vehicles used to deliver topical therapies can profoundly impact drug penetration, efficacy, patient acceptance, and treatment adherence. Therefore...
Read More

An Open-Label Pilot Study to Investigate Safety and Efficacy of Fixed Combination Tazarotene 0.045% and Halobetasol Propionate 0.01% Lotion for the Treatment of Scalp Psoriasis

November 2021 | Volume 20 | Issue 11 | Original Article | 1191 | Copyright © November 2021

Up to 80% of individuals with plaque psoriasis have scalp involvement, which can have a significant impact on the quality of life of affected individuals. Despite advancements in psoriasis therapeutic...
Read More

INDIVIDUAL ARTICLE: Safety and Tolerability of Topical Agents for Actinic Keratosis: A Systematic Review of Phase 3 Clinical Trials

October 2021 | Volume 20 | Issue 10 | Supplement Individual Articles | s4s4 | Copyright © October 2021

Background: Topical agents for actinic keratosis (AK), along with cryotherapy and phototherapy, are the most commonly used therapies for areas of skin with multiple AKs. Multiple opti...
Read More

ARTICLE: Why Absorica LD?

May 2021 | Volume 20 | Issue 5 | Supplement Individual Articles | 3s | Copyright © May 2021

Read More

Oral Sarecycline for Treatment of Papulopustular Rosacea: Results of a Pilot Study of Effectiveness and Safety

April 2021 | Volume 20 | Issue 4 | Original Article | 426 | Copyright © April 2021

Background: Cutaneous rosacea is a common inflammatory skin disorder that often presents with facial papulopustular lesions that are frequently bothersome to patients. Studies have sh...
Read More

Effects of Tazarotene 0.045% Lotion on Quality of Life in Patients With Moderate-to-Severe Acne

November 2020 | Volume 19 | Issue 11 | Original Article | 1086 | Copyright © November 2020

Background: In two phase 3 trials (NCT03168334, NCT03168321), participants with moderate-to-severe acne had significant symptom improvements after 12 weeks of treatment with tazaroten...
Read More

ARTICLE: Oral Tetracyclines and Acne: A Systematic Review for Dermatologists

November 2020 | Volume 19 | Issue 11 | Supplement Individual Articles | s6 | Copyright © November 2020

Oral tetracyclines are the most widely prescribed systemic antibiotic for acne. Synthesis of efficacy and safety of traditional and novel oral tetracyclines is highly informative to clinical practice....
Read More

ARTICLE: A Novel Antibiotic Just for Acne

November 2020 | Volume 19 | Issue 11 | Supplement Individual Articles | s5 | Copyright © November 2020

Dermatologists consistently rank as the most frequent prescribers of systemic antibiotics, and one of the most common diagnoses for which we recommend these agents is acne vulgaris. Up to three quarte...
Read More

Once-Daily Polymeric Tazarotene 0.045% Lotion for Moderate-to-Severe Acne: Pooled Phase 3 Analysis by Sex

August 2020 | Volume 19 | Issue 8 | Original Article | 777 | Copyright © August 2020

Background: Two identical phase 3 randomized, double-blind, vehicle-controlled, 12-week studies (NCT03168321 and NCT03168334) demonstrated the efficacy and safety of tazarotene 0.045%...
Read More

Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities

April 2020 | Volume 19 | Issue 4 | Original Article | 389 | Copyright © April 2020

Background: Plaque psoriasis can occur in all body regions, with the trunk and extremities among the most commonly affected areas. A fixed combination halobetasol propionate 0.01%/taz...
Read More

ARTICLE: Game Changer in Acne Treatment

March 2020 | Volume 19 | Issue 3 | Supplement Individual Articles | 28 | Copyright © March 2020

Of the four primary pathogenic factors that drive acne vulgaris—androgen excess, increased sebum production, faulty keratinization, and overgrowth of C. acnes—androgen excess has been the ...
Read More